Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 19Terminated 3Active not recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other solid neoplasm 1Breast 1

Conditions

Hematopoietic and Lymphatic System Neoplasm 1Breast Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Bupropion × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT03996265 2026-01-15

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

University of Rochester

Phase 3 Active not recruiting
422 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡